Business Context and Reporting Period
Company: Moolec Science SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 21, 2025
Reporting Period: October 2025
Context: The filing discloses a potential legal dispute regarding a failed transaction involving an Assignment and Assumption Agreement dated May 27, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a legal contingency.
Material Changes and Contingencies
- Dispute Initiation: On October 2, 2025, Moolec received a notice of alleged breach from INVIM Corporativo S.L. regarding an Assignment and Assumption Agreement.
- Alleged Amount: INVIM asserts that Obligors (Bioceres Group Limited and Bioceres Tech Services LLC) failed to pay an Assignment Price of $13 million due on September 30, 2025.
- Company Position: Moolec disputes the claim, stating that INVIM failed to satisfy conditions precedent, including the valid transfer of securities and execution of a required services agreement.
- Response: On October 20, 2025, Moolec delivered a formal response rejecting INVIM's assertions and reserving all rights.
Outlook, Risks, and Management Commentary
Management intends to vigorously defend its position and enforce its rights under the Agreement and applicable law. While Moolec believes INVIM's assertions lack merit, the filing warns that an adverse outcome in any proceedings could have a material adverse effect on the Company's business, financial condition, results of operations, or liquidity. No financial guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the status of the $13 million payment obligation and the specific conditions precedent cited by Moolec as unmet.
- Monitor for further legal developments or updates regarding the dispute with INVIM Corporativo S.L.
- Assess the potential impact of an adverse legal ruling on Moolec's liquidity and financial condition.
- Review the underlying Assignment and Assumption Agreement (May 27, 2025) and related instruments (Note Purchase Agreement, Binding Contribution Memorandum of Understanding) for context.